

Review article

Restless Legs Syndrome and Iron

Josipa Pulić*¹¹ Institute of Emergency Medicine of Koprivnica- Križevci County, Koprivnica, Croatia

*Corresponding author: Josipa Pulić, pulic.josipa@gmail.com

Abstract

Restless legs syndrome (RLS), also known as Willis-Ekbom disease, is one of the most common neurological disorders that significantly affects quality of life and sleep. It manifests itself in involuntary movements of the lower limbs due to the feeling of discomfort and restlessness that patients feel in their lower limbs.

RLS is of great interest to the experts in various fields of medicine, especially to neurologists, general practitioners, internists and psychiatrists. Numerous clinical conditions and diseases play a role in the pathophysiology of RLS. Some of them are pregnancy, some kidney and stomach diseases, iron deficiency and some disorders of the metabolism.

Moreover, iron is a very important micronutrient in the human body. It is involved in many metabolic processes and, in addition to RLS, it is also associated with other diseases such as hemochromatosis and anemia. This neurological disorder has wide therapeutic choices, which include lifestyle changes, dopaminergic agonists, opioids and iron therapy. Many non-anemic patients with RLS showed reduced levels in brain iron levels compared to healthy control groups in several research. The best course of treatment for this group of patients is iron supplementation.

Oral iron supplementations are the first choice of therapy for patients with low serum ferritin levels. However, when serum ferritin levels are normal or high or when oral iron is not tolerated, intravenous iron is a better choice. There are many intravenous iron formulations, but low molecular weight dextran and ferric carboxymaltose have very efficient effects on the treatment of RLS.

(Pulić * J. Restless Legs Syndrome and Iron. SEEMEDJ 2020; 4(1); 55-62)

Received: Feb 21, 2020; revised version accepted: Mar 18, 2020; published: Apr 27, 2020

KEYWORDS: restless legs syndrome, Willis-Ekbom disease, iron metabolism, serum ferritin levels, treatment

Introduction

Restless legs syndrome (RLS) has been described as a neurological disorder, related to uncontrolled leg movements, and, in much smaller number of patients, it is associated with uncontrolled hand movements. Uncontrolled limb movements are preceded by a sense of discomfort, described by patients as annealing, burning, tickling, etc. It occurs more frequently during inaction. Therefore, it is a common cause of sleep disorders (1-3). In the 17th century, sir Thomas Willis noticed the connection between sleep disorders and lower extremity discomfort among his patients. However, Karl- Axel Ekbohm first used the term 'restless legs syndrome' in 1945. That is why this disorder is also known as Willis-Ekbohm disease (4).

Unlike some other disorders with similar problems, such as polyneuropathy, the symptoms of RLS decrease with leg movements. In most cases, it is a chronic

disorder with worsening symptoms, which vary in intensity and frequency. Therefore, in patients with chronic form of this disorder, symptoms occur at least twice a week if patients do not follow their therapy (1, 5).

RLS has prevalence between 8 and 10% (6) in adult and 2% in children population (7). The study conducted by Manconi et al. has shown that RLS occurs more frequently in women, age 35 and above, than in men of the same age (8).

This disorder can be inherited or be a result of a clinical condition such as kidney diseases (hemodialysis patients) (9), pregnancy (evaluated progesterone and estrogen levels, iron deficiency) (10), anemia, stomach damage, etc. In addition, some substances such as neuroleptic drugs, caffeine, lithium, metoclopramide, antihistamines, dopaminergic agents (1, 11) may increase the risk of developing RLS symptoms (Figure 1).




Figure 1. Non-hereditary causes of restless legs syndrome

Summarized findings from studies to date on the most common diseases/clinical conditions/drugs that are associated with restless legs syndrome.

Treatment for RLS depends on its cause. Therefore, the treatment can include

dopaminergic agents, lifestyle changes, iron therapy, α -2- δ -ligands, opioids, etc (1).

Compared to the previous European Federation of Neurological Societies (EFNS) guidelines on the management of RLS from 2004, new guidelines from 2012 bring news. Numerous drug studies have been made during this period and new treatments have been examined that could be a potential therapy for RLS. The majority of research deals with dopaminergic agents, considered the first line therapy. The crucial role of iron in pathophysiology of RLS has also been confirmed. Alternative forms of therapy have been investigated; folate, vitamin E, physiotherapy, aerobic training and magnesium. Nevertheless, there is still not enough evidence of their effectiveness (12).

Iron in relation to health and diseases

Iron is one of the most important micronutrient in human body. It has many functions such as a role in metabolic processes; it can cause oxidative stress because it participates in the formation of oxygen radicals (13), and it is a cofactor of numerous enzymes (13, 14).

There are about 4,2 grams of iron in the human body, and much of it is bound to hemoglobin and involved in oxygen transfer (12). About 10% of the iron ingested through food is absorbed in the digestive system, mostly in the duodenum (15).

Ferritin is an intracellular protein that stores iron and plays an important role in regulating iron homeostasis, while transferrin is a glycoprotein that binds iron and transports it into the cells (16). The major regulator of iron homeostasis is hepcidin, 25-amino acid peptide hormone, which is mainly secreted by hepatocytes (17, 18). Its deregulation is linked with excess iron and iron deficiency. Therefore, when level of hepcidin is very high, like in case of inflammation, the absorption of iron is reduced and this can lead to the development of anemia (17-19).

It is proved that brain and liver contain high levels of iron (13). The highest concentration of brain iron is found in substantia nigra, globus pallidus, red nucleus, putamen and dentate nucleus of the cerebellum (20, 21). In

oligodendrocytes, the presence of the transferrin has been confirmed, but a greater amount of brain iron is nevertheless related with ferritin (13, 22). Iron plays a large role in neurotransmitter synthesis and mitochondrial respiration and its status is regulated at the level of the blood- brain barrier (BBB) (13, 23, 24).

It has long been known that iron excess causes hemochromatosis, characterized by skin changes, weakness, loss of sex drive, abdominal pain and symptoms of diabetes; but recent studies have associated brain iron excess with the onset of neurodegenerative diseases such as Parkinson's disease. On the other hand, iron deficiency in the central nervous system (CNS) is associated with irritability, concentration disorder, tiredness and it may play a role in the pathophysiology of RLS (13).

Correlation between restless legs syndrome and iron

The first person who noticed that low serum iron level could be a risk factor for developing restless legs syndrome was Nordlander (25, 26). Ekbom observed iron deficiency among his patients. Although he noticed repeated occurrence of low iron level in RLS, most of his patients suffered from uremia, anemia or were pregnant women (27). In another research, O'Keefe found low serum iron and ferritin values in patients who complained of RLS symptoms. It was observed that the lower the ferritin level were, the more severe RLS symptoms appeared (28, 29). Iron supplementation has caused improvement in some patients. The potential cause of this is altered management of brain iron in patients with RLS (30, 31).

Two studies have shown that almost 2/5 of the patients suffering from iron deficiency anemia also had symptoms of RLS. Nevertheless, these studies used small groups of participants (32, 33). However, one study, conducted by Allen et al. among the general population, has shown that the percentage of people with symptoms of RLS is several times higher in the group of participants with iron deficiency anemia than in the general population (34). Abnormalities in the

concentrations of ferritin, transferrin in the cerebrospinal fluid (CSF), low CSF ferritin, and high CSF transferrin levels have been noticed (35).

Circadian pattern is characteristic for RLS, with symptoms being dominant at nighttime. Serum iron has a circadian variation, with 30 to 50% drop at night. This can lead to clinically significant drop in brain iron levels with patients with RLS and create the symptoms (36).

Lower iron concentration in substantia nigra and putamen were found in some patients with idiopathic RLS and capillary transport of iron in the brain probably plays a major role in this. In addition, it has been observed that the iron levels in substantia nigra increase with aging (37-39).

There is a small number of studies that have compared the connection between serum hepcidin levels and RLS. However, one of them found higher prohepcidin (inactive form of hepcidin) in putamen and substantia nigra in patients with RLS. This opens up the possibility of discovering new medications, such as hepcidin antagonists, for the treatment of RLS (40-42).

Iron treatment

Iron deficiency anemia is present in more than 1/5 of the patients with RLS (34). Accordingly, oral and intravenous iron supplements are used as therapy for those patients. When serum ferritin level is lower than 75 $\mu\text{g/L}$, oral iron supplementation is the therapy of choice. While in patients with serum ferritin level higher than 300 $\mu\text{g/L}$ intravenous iron preparations are a better choice (43, 44). O'Keeffe observed among his patients, who had different serum ferritin values, that oral iron supplements had better effect on patients with lower serum ferritin values. However, the problem with this study was that it did not have a control group (25, 29). Furthermore, oral iron supplements have almost the same effect whether taken once a day or divided into two doses. In addition, in both cases these supplementations should be taken with

vitamin C in order to improve absorption in the small intestine (44, 45).

According to the American Academy of Sleep Medicine (AASM) guidelines, iron treatment is effective for RLS only in patients who have low ferritin levels. In addition, it is preferred oral over parenteral iron formulations, because parenteral forms are associated with a number of side effects that can endanger patients' life and health (46).

On the other hand, intravenous iron supplementations bypass the intestinal- blood barrier and restriction of iron absorption (47). Intravenous iron forms take precedence over oral iron only in two cases. First is when the patient is severely bleeding and rapidly losing iron, and the second case is when patients have problems with oral iron absorption (44, 48).

There are several intravenous iron formulations available: ferric carboxymaltose, iron sucrose, iron gluconate, low and high molecular weight dextrans (LMW and HMW dextrans), ferumoxytol and iron isomaltose (44). LMW dextran and ferric carboxymaltose have the best clinical evidences for treatment of RLS (1, 44). Infusion of 1000 mg LMW dextran improves the health of RLS patients with early symptoms and significantly increases iron levels in substantia nigra (49). Both oral and intravenous iron preparations have numerous limitations in the treatment of RLS. The most dangerous side effect is related to HMW dextran and it involves anaphylactic shock. On the other hand, ferric carboxymaltose is safe to use because its side effects, such as nausea and headache, are much milder (50).

There are not enough studies on intravenous sucrose, as well as on most intravenous iron preparations. Nevertheless, it is known that intravenous sucrose is not effective for patients that do not have anemia (50). In addition, for iron gluconate, ferumoxytol and iron isomaltose, there are insufficient clinical evidences (44, 51) (Table 1).

Table 1. Iron preparation limitations in the treatment of restless legs syndrome

Oral ferrous sulfate:	gastrointestinal upset; not effective for patients with serum ferritin level >75 µg/l
Ferric carboxymaltose:	headache nausea
Iron sucrose:	not effective in iron deficiency patients without anemia
High molecular weight dextran:	high incidence of anaphylactic shock
Low molecular weight dextran:	not so effective in patients with symptoms of late onset RLS
Iron isomaltose, ferumoxytol, iron gluconate:	not enough clinical evidences

Note: Summarized findings from studies to date on oral and intravenous iron preparations for the treatment of restless legs syndrome.

Avni et al. have proven in their research that iron preparations are safe and effective for RLS. However, there is still a great need for further research, especially for the research that could determine the exact drug dosages and therapeutic regimen (43)

Conclusion

Numerous studies on the relationship between RLS and iron in the body have provided better insight into the pathophysiology of this disorder and have opened up new possibilities related to therapeutic approaches, such as hepcidin antagonists. Nevertheless, there are still many

uncertainties related to iron therapy and a need for further research on that topic. The reason is the fact that many intravenous iron formulations lack sufficient clinical evidences regarding their effect on reducing the symptoms of RLS. Furthermore, many studies have a small or inadequate sample of participants. In addition, for many intravenous iron formulations the exact dosage required for the treatment of RLS has not been determined..

References

1. During EH, Winkelman JW. Drug treatment of restless legs syndrome in older adults. *Drugs Aging* 2019; 36(10):939-46.
2. Walters AS, Hickey K, Maltzman J, Verrico T, Joseph D, Hening W, Wilson V, Chokroverty S. A questionnaire study of 138 patients with restless legs syndrome: the "night-walkers" survey. *Neurology* 1996; 46(1): 92-5.
3. Allen RP, Picchietti DL, Garcia-Borreguero D, Ondo WG, Walters AS, Winkelman JW, Zucconi M, Ferri R, Trenkwalder C, Lee HB; International Restless Legs Syndrome Study Group. Restless legs syndrome/Willis Eckbom disease diagnostic criteria: update Interantional Restless Legs Syndrome Study Group (IRLSSG) consensus criteria- history, rationale, description, and significance. *Sleep Med* 2014; 15(8): 860-73.
4. Coccagna G, Ventrugno R, Lombardi C, Provini F. Restless legs syndrome: an historical note. *Sleep Med* 2004; 5(3): 279-83.
5. Gonzales- Latapi P, Malkani R. Update on restless legs syndrome: from mechanisms to treatment. *Curr Neurol Neurosci Rep* 2019; 19(8):54.
6. Early CJ, Allen RP, Beard JL, Connor JL. Insight into the pathophysiology of restless legs syndrome. *J Neurosci Res* 2000; 62(5): 623-8.
7. Sander HH, Eckeli AL, Costa Passos AD, Azevedo LL, Fernandes do Prado LB, Franca Fernandes RM. Prevalence and quality of life and sleep in children and adolescents with restless legs syndrome/Willis-Ekbom disease. *Sleep Med* 2017; 30: 204-9.
8. Manconi M, Ulfberg J, Berger K, Ghorayeb I, Wesström J, Fulda S, Allen RP, Pollmächer T. When gender matters: restless legs syndrome. Report of the "RLS and women" workshop endorsed by the European RLS Study Group. *Sleep Med Rev* 2012; 16(4): 297-307.
9. Mucsi I, Molnar MZ, Rethelyi J, Vamos E, Csepanyi G, Tompa G, Barotfi S, Marton A, Novak M. Sleep disorders and illness intrusiveness in patients on chronic dialysis. *Nephrol Dial Transplant* 2004; 19(7): 1815-22.
10. Gupta R, Dhyani M, Kendzerska T, Pandi-Perumal SR, BaHamam AS, Srivanitchapoom P, Pandey S, Hallett M. Restless legs syndrome and pregnancy: prevalence, possible pathophysiology mechanisms and treatment. *Acta Neurol Scand* 2016; 133(5): 320-9.
11. Trenkwalder C, Allen R, Hogl B, Paulus W, Winkelmann J. Restless legs syndrome associated with major diseases: A systematic review and new concept. *Neurology* 2016; 84(14): 1336-43.
12. Garcia-Borreguero D, Ferini-Strambi L, Kohnen R, O'Keefe S, Trenkwalder C, Högl B, Benes H, Jennum P, Partinen M, Fer D, Montagna P, Bassetti CL, Iranzo A, Sonka K, Williams AM; European Federation of Neurological Societies; European Neurological Society; European Sleep Research Society. European guidelines on management of restless legs syndrome: report of a joint task force by the European Federation of Neurological Societies, the European Neurological Society and the European Sleep Research Society. *Eur J Neurol* 2012; 19(11): 1385-96.
13. Krieger J, Schroeder C. Iron, brain and restless legs syndrome. *Sleep Med Rev* 2001; 5(4): 277-86.
14. Youdim MBH, Ben-Sachar D, Riederer P. Iron in brain function and dysfunction with emphasis on Parkinson's disease. *Eur Neurol* 1991; 31(1): 34-40.
15. Radman I, Vodanović M, Inga Mandac-Rogulj, Jelena Roganović, Duška Petranović, Toni Valković, Slobodanka Ostojić Kolonić, Vlatko Pejša, Rajko Kušec, Igor Aurer. Croatian hematology society and CROHEM guidelines for the treatment of iron deficiency anemia. *Liječ Vjesn* 2019; 141: 1-13.
16. PDB101. Molecule of the month. Ferritin and transferrin. <https://pdb101.rcsb.org/motm/35> (last accessed on 02/19/2020).

17. Ganz T. Hepcidin, a key regulator of iron metabolism and mediator of anemia of inflammation. *Blood* 2003; 102(3): 783-8.
18. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, Ganz T, Kaplan J. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. *Science* 2004; 306(5704): 2090-3.
19. Nemeth E, Ganz T. The role of hepcidin in iron metabolism. *Acta Haematol* 2009; 122(23): 78-86.
20. Martin WR, Ye FQ, Allen PS. Increasing striatal iron content with normal aging. *Mov Disord* 1998; 13(2): 281-6.
21. Koepfen AH. The history of iron in the brain. *J Neurol Sci* 1995; 143(Suppl): 1-9.
22. Han J, Day JR, Thompson K, Connor JR, Beard JL. Iron deficiency alters H- and L-ferritin expression in rat brain. *Cell Mol Biol* 2000; 46(3): 517-28.
23. Duck KA, Neely EB, Simpson IA, Connor JR. A role for sex and a common HFE gene variant in brain iron uptake. *J Cereb Blood Flow Metab* 2018; 38(3): 540-8.
24. McCarthy RC, Kosman DJ. Mechanistic analysis of iron accumulation by endothelial cells of the BBB. *Biometals* 2012; 25(4): 665-75.
25. Early CJ. Hemochromatosis and iron therapy of restless legs syndrome. *Sleep Med* 2001; 2(3): 181-3.
26. Nordlander NB. Therapy in restless legs. *Acta Med Scand* 1953; 145(6): 453-7.
27. Ekblom KA. Restless legs syndrome. *Neurology* 1960; 10: 868-73.
28. Berger K, von Eckardstein A, Trenkwalder C, Rothdach A, Junker R, Weiland SK. Iron metabolism and the risk of restless legs syndrome in an elderly general population – the MEMO-Study. *J Neurol* 2002; 248(9): 1195-9.
29. O'Keefe ST, Gavin K, Lavan JN. Iron status and restless legs syndrome in the elderly. *Age Ageing* 1994; 23(3) 200-3.
30. Lammers N, Curry-Hyde A, Smith AJ, Eastwood PR, Straker LM, Champion D, McArdle N. Are serum ferritin and transferrin saturation risk markers for restless legs syndrome in young adults? Longitudinal and cross-sectional data from the Western Australian Pregnancy Cohort (Raine) Study. *J Sleep Res* 2019; 28(5):e12741. doi: 10.1111/jsr.12741.
31. Connor JR, Menzies SL. Cellular management of iron in the brain. *J Neurol Sci* 1995; 134 (Suppl): 33-44.
32. Aspenstroem G. Picca and restless legs in iron deficiency. *Sven Lakartidn* 1964; 61: 1174-7.
33. Akyol A, Klylioglu N, Kadikoylu G, Bolaman AZ, Ozgel N. Iron deficiency anemia and restless legs syndrome: Is there an electrophysiological abnormality? *Clin Neurol Neurosurg* 2003; 106(1): 23-7.
34. Allen RP, Auerbach S, Bahrain H, Auerbach M, Early CJ. The prevalence and impact of restless legs syndrome on patients with iron deficiency anemia. *Am J Hematol* 2013; 88(4): 261-4.
35. Early CJ, Connor JR, Beard JL, Malecki EA, Epstein DK, Allen RP. Abnormalities in CSF concentrations of ferritin and transferrin in restless legs syndrome. *Neurology* 2000; 54(8): 1698-1700.
36. Tarquini B. Iron metabolism: clinical chronobiological aspects. *Chronobiologia* 1978; 5(3): 315-36.
37. Bartzokis G, Cummings JL, Markham CH, Marmarelis PZ, Treciakos LJ, Tishler TA, Marder SR, Mintz J. MRI evaluation of brain iron in earlier- and later onset Parkinson's disease and normal subjects; *Magn Reson Imaging* 1999; 17(2): 213-22.
38. Zucca FA, Bellei C, Giannelli S, Terreni MR, Gallorini M, Rizzio E, Pezzoli G, Albertini A, Zecca L. Neuromelanin and iron in human locus coeruleus and substantia nigra during aging: consequences for neuronal vulnerability. *J Neural Transm* 2006; 113(6): 757-67.
39. Snyder AM, Connor JR. Iron, the substantia nigra and related neurological

disorders. *Biochim Biophys Acta* 2009; 1790(7): 606-14.

40. Dauvilliers Y, Chenini S, Vialaret J, Delaby C, Guiraud L, Gabelle A, Lopez R, Hirtz C, Jaussent I, Lehmann S. Association between serum hepcidin level and restless legs syndrome. *Mov Disord* 2018; 33(4):618-627. doi: 10.1002/mds.27287.

41. Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. *Front Pharmacol* 2014; 5:86.

42. Clardy SL, Wang X, Boyer PJ, Earley CJ, Allen RP, Connor JR. Is ferroportin-hepcidin signaling altered in restless legs syndrome? *J Neurol Sci* 2006; 247(2): 173-9.

43. Avni T, Reich S, Lev N, Gafter-Gvili A. Iron supplementation for restless legs syndrome: A systematic review and meta-analysis. *Eur J Intern Med* 2019; 63: 34-41.

44. Allen RP, Picchiatti DL, Auerbach M, Cho YW, Connor JR, Earley CJ, Garcia-Borreguero D, Kotagal S, Manconi M, Ondo W, Ulfberg J, Winkelmann JW; International Restless Legs Syndrome Study Group (IRLSSG). Evidence based and consensus clinical practice guidelines for the iron treatment of restless legs syndrome/Willis-Ekbom disease in adults and children: an IRLSSG task force report. *Sleep Med* 2018; 41: 27-44.

45. Moretti D, Goede JS, Zeder C, Jiskra M, Chatzinakou V, Tjalsma H. Oral iron supplements increase hepcidin and decrease iron absorption

from daily or twice-daily doses in iron-depleted young women. *Blood* 2015; 126(17): 1981-9.

46. Aurora RN, Kristo DA, Bista SR, Rowley JA, Zak RS, Casey KR, Lamm CI, Tracy SL, Rosenberg RS; American Academy of Sleep Medicine. The treatment of restless legs syndrome and periodic limb movement disorder in adults- an update from 2012: practice parameters with an evidence-based systematic review and meta-analyses. *Sleep* 2012; 35(8): 1039-62.

47. Jimenez K, Kulnigg-Dabsch S, Gasche C. Management of iron deficiency anemia. *Gastroenterol Hepatol* 2015; 11(4): 241-50.

48. De Biase S., Pellitteri G, Gigli GL, Valente M. Advancing synthetic therapies for the treatment of restless legs syndrome. *Expert Opin Pharmacother* 2019; 20(16): 1971-80.

49. Early CJ, Heckler D, Allen RP. The treatment of restless legs syndrome with intravenous iron dextran. *Sleep Med* 2004; 5(3): 231-5.

50. Winkelmann J, Allen RP, Högl B, Inoue Y, Oertel W, Salminen AV, Winkelmann JW, Trenkwalder C, Sampaio C. Treatment of restless legs syndrome: Evidence-based review and implications for clinical practice (Revised 2017). *Mov Disord* 2018; 33(7):1077-1091. doi: 10.1002/mds.27260.

51. Grote L, Leissner L, Hedner J, Ulfberg J. A randomized, double-blind, placebo controlled, multi-center study of intravenous iron sucrose and placebo in treatment of restless legs syndrome. *Mov Disord* 2009; 24(10): 1445-52.